Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Kelly, R.; Ajani, J.; Kużdżał, J.; Zander, T.; Van Cutsem, E.; Piessen, G.; Mendez, G.; Feliciano, J.; Motoyama, S.; Lièvre, A.; Uronis, H.; Elimova, E.; Grootscholten, C.; Geboes, K.; Zafar, S.; Snow, Stephanie; Ko, A.; Feeney, K.; Schenker, M.; Kocoń, Piotr; Zhang, Jenny; Zhu, Lili; Lei, M.; Singh, Prianka; Kondo, K.; Cleary, J.; Moehler, M.

doi:10.1056/NEJMoa2032125

Public

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Shared by NobleBlocks on Apr 1, 2021 • 12:00 AM UTC

Authors:

R. Kelly

J. Ajani

J. Kużdżał

Abstract

BACKGROUND No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. METHODS We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled pha...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!